Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Danish pharmaceutical company Novo Nordisk on Tuesday launched its once-weekly injectable weight-loss drug Wegovy in India, at Rs 4,336.25 per dose. Wegovy, a once-weekly glucagon-like peptide-1 ...

Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks.

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said ...

Over the past two decades, India has seen a sharp rise in obesity among women, particularly in urban areas. According to the National Family Health Survey (NFHS-5), nearly 24% of Indian women aged ...

Study highlights rising obesity rates among Indian women, urging urgent public health action to address fertility and long-term health risks. Nearly half of Indian women aged 35–49 are ...

Causes of Abdominal Obesity. One of the biological drivers of this crisis lies in how South Asians, including Indians, store fat. Research shows that compared to white Caucasians with the same ...